<- Go Home
4basebio PLC
4basebio PLC engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and targeted non-viral vector solutions in the United States, Europe, and internationally. The company offers AVV and Lentivirus manufacturing services for use in gene therapies and vaccines. It also offers access to its targeted non-viral delivery platform, Hermes. The company was formerly known as 4basebio UK Societas and changed its name to 4basebio PLC in July 2021. 4basebio PLC was founded in 2008 and is based in Cambridge, the United Kingdom.
Market Cap
GBP 144.1M
Volume
2.9K
Cash and Equivalents
GBP 2.7M
EBITDA
-GBP 9.6M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
GBP 415.0K
Profit Margin
69.63%
52 Week High
GBP 18.20
52 Week Low
GBP 10.20
Dividend
N/A
Price / Book Value
-27.61
Price / Earnings
-14.31
Price / Tangible Book Value
-23.87
Enterprise Value
GBP 156.8M
Enterprise Value / EBITDA
-16.51
Operating Income
-GBP 10.2M
Return on Equity
1088.88%
Return on Assets
-54.30
Cash and Short Term Investments
GBP 2.7M
Debt
GBP 15.5M
Equity
-GBP 5.2M
Revenue
GBP 596.0K
Unlevered FCF
-GBP 6.7M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium